Novo Nordisk once weekly insulin icodec bests Tresiba in lowering blood sugar (NYSE:NVO) | Seeking Alpha
Novo Nordisk 2022: Expanding capabilities – PharmaLive
Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing | BMJ Open Diabetes Research & Care
Novo Nordisk reaches primary endpoint in phase III of once-weekly insulin — MedWatch
Once-weekly insulin icodec demonstrates superior reduction in HbA1c in combination with a dosing guide app versus once-daily basal insulin in people with type 2 diabetes in ONWARDS 5 phase 3a trial
Novo Nordisk Once-weekly Insulin Icodec Shows Comparable Efficacy To Once-daily Insulin Glargine U100 in Phase 2 trial
Once-weekly insulin efficacy similar to daily therapy in type 2 diabetes
Novo Nordisk achieves primary objectives of ONWARDS 3 and 4 trials with once-weekly insulin icodec demonstrating superior reduct
Novo Scores Phase III Insulin Icodec Win, Potentially Strengthening Market Position | BioSpace
Rationale and design of the phase 3a development programme (ONWARDS 1–6 trials) investigating once‐weekly insulin icodec in diabetes - Philis‐Tsimikas - Diabetes, Obesity and Metabolism - Wiley Online Library
Novo Nordisk's icodec therapy delivers positive data - PharmaTimes
Insulin Icodec - the once a week long acting insulin from Novo Nordisk | Diabettech - Diabetes and Technology
Insulin icodec: an insulin analogue suited for once-weekly dosing in type 2 diabetes - Media Centre | EASD
Molecular Engineering of Insulin Icodec, the First Acylated Insulin Analog for Once-Weekly Administration in Humans | Journal of Medicinal Chemistry
Insulin Icodec - the once a week long acting insulin from Novo Nordisk | Diabettech - Diabetes and Technology
Novo Nordisk poised to fire on all new GLP1 cylinders following the fourth quarter of 2019, but shares fairly valued - MidgardFinance.com
Once-Weekly Insulin Icodec Promising for Type 2 Diabetes - Consumer Health News | HealthDay
Novo Nordisk når endemål i fase 3 for ugentligt insulin — MedWatch
Primary objectives of ONWARDS 1 and 6 trials with once-weekly insulin
The promising future of insulin therapy in diabetes mellitus | American Journal of Physiology-Endocrinology and Metabolism
Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment | NEJM
Novo Nordisk bolstered by another late-stage trial of once weekly insulin icodec (NVO) | Seeking Alpha
